Search research articles
Contact Us
Filters
Showing results (191-200 of 244) with videos related to
Page
of 25
Sort By:
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
February 1, 1992
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer
M S Negrier, C N Pourreau, P A Palmer, et al.
British Journal of Cancer
|
March 1, 1992
Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation
B Richard, M C Launay-Iliadis, A Iliadis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2013
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer
S T Ligthart, F-C Bidard, C Decraene, et al.
European Cytokine Network
|
February 12, 1998
Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation
N Vey, P Viens, C Fossat, et al.
Bone Marrow Transplantation
|
June 1, 2002
Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation
A C Braud, M P Mathoulin Portier, V J Bardou, et al.
Bone Marrow Transplantation
|
August 26, 1998
Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation
C Faucher, C Fortanier, P Viens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2006
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
P Viens, T Petit, A Yovine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape
B Escudier, C Chevreau, C Lasset, et al.
Bone Marrow Transplantation
|
January 31, 2007
High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation
J El-Cheikh, C Faucher, S Fürst, et al.
European Cytokine Network
|
June 5, 1998
Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer
P Viens, D Genre, C Protière, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 244) with videos related to
Sort By:
Page
of 25
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
February 1, 1992
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer
M S Negrier, C N Pourreau, P A Palmer, et al.
British Journal of Cancer
|
March 1, 1992
Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation
B Richard, M C Launay-Iliadis, A Iliadis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2013
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer
S T Ligthart, F-C Bidard, C Decraene, et al.
European Cytokine Network
|
February 12, 1998
Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation
N Vey, P Viens, C Fossat, et al.
Bone Marrow Transplantation
|
June 1, 2002
Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation
A C Braud, M P Mathoulin Portier, V J Bardou, et al.
Bone Marrow Transplantation
|
August 26, 1998
Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation
C Faucher, C Fortanier, P Viens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2006
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
P Viens, T Petit, A Yovine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape
B Escudier, C Chevreau, C Lasset, et al.
Bone Marrow Transplantation
|
January 31, 2007
High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation
J El-Cheikh, C Faucher, S Fürst, et al.
European Cytokine Network
|
June 5, 1998
Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer
P Viens, D Genre, C Protière, et al.
Page
of 25